CORONA Remedies IPO: Should you apply?

Summary: CORONA Remedies, a pharma company, is set to go public on December 8, 2025. Let’s break down the company’s strengths, weaknesses and past performance to help you decide whether its IPO is worth your money.

CORONA Remedies, a pharmaceutical formulation company, will open its IPO (initial public offering) on December 8, 2025 and close on December 10, 2025. Its issue size, worth Rs 655 crore, will entirely be an offer for sale (OFS).

Here, we analyse the company’s strengths, weaknesses, financial track record and past valuations to help you make an informed investing decision.

What the company does

CORONA Remedies is a branded formulation company focused on women’s health, cardio-diabeto, pain management, urology and other specialty therapies. It is among the fastest-growing players in the Indian pharmaceutical market, with strong volume gains and steady new product launches being key growth drivers.

The company markets 71 brands, anchored by 27 ‘engine’ brands that contribute over 70 per cent of domestic sales. Several of its core brands, including Myoril, Cor and Trazer, rank at the top of their respective sub-groups. Its portfolio is skewed towards chronic and sub-chronic therapies, which form about 70 per cent of domestic sales.

Track record and valuation

CORONA Remedies’ financial performance during FY23-25 shows that the company has been on steady ground. While revenue grew at over 16 per cent annually over the three-year period, net income (profit after tax) and EBIT (earnings before interest and tax) surged by 33 per cent and 37 per cent, respectively, during the same period.

At the upper end of the price band (Rs 1,062), CORONA Remedies’ stock is expected to be valued at 43.5 times its FY25 earnings and 10.7 times its book value. In comparison, CORONA Remedies’ peers trade at a P/E and P/B of 40.7 times and 11 times, respectively.

The good

Here are some of the strengths of CORONA Remedies.

#1 A fast-growing player in the pharmaceutical space

CORONA Remedies is the second fastest-growing company among the top 30 in the Indian pharmaceutical market, with domestic sales growing at 16.77 per cent between June 2022 and June 2025, well ahead of industry growth. Strong momentum has come from a higher share of successful new product launches and sustained focus on high-growth therapeutic areas.

A larger proportion of its portfolio sits in the growth stage of the product life cycle, compared to the broader market. This strategic positioning has helped lift sales across all its key therapy segments.

#2 Extensive sales and distribution network

The company has built a pan-India sales and marketing network focused on the ‘middle of the pyramid’ segment across urban and semi-urban markets. This strategy, centred on specialist and super-specialist doctors, has helped it grow prescriptions faster than the overall Indian pharma market. Urban and semi-urban regions now contribute over 75 per cent of domestic sales.

CORONA Remedies is also the third fastest-growing player in prescriptions within key targeted specialties. A growing field force of more than 2,600 medical representatives enables deeper engagement with hospitals and clinicians, strengthening its presence across therapeutic areas.

The bad

Here are some of CORONA Remedies’ drawbacks.

#1 Revenue is largely dependent on a handful of products

Women’s healthcare, cardio-diabeto and pain management form the company’s core revenue drivers, contributing about 65 per cent of sales for the quarter ended June 2025 and over 62 per cent in FY25. A slowdown in these therapy areas or rising competition could materially affect performance.

CORONA Remedies’ growth is also heavily dependent on its 27 ‘engine’ brands, which comprise over 72 per cent of domestic sales. Key brands such as B-29 and Myoril play a central role in this mix. Any weakness in these flagship brands could impact revenue, profitability and cash flows.

#2 Geographical concentration

CORONA Remedies remains heavily India-dependent, with over 96 per cent of its revenue coming from the domestic market alone. Any slowdown in demand, rising competition or pricing pressure in India could materially impact its performance.

The business also faces broader risks such as supply fluctuations, renewed infectious disease outbreaks and the growing adoption of generics and government schemes like PMJAY. While these factors have not affected recent performance, they remain potential headwinds. The company’s ability to scale into international markets is still unproven, and delays here could further constrain growth.

Where will the IPO proceeds go?

Since the IPO is completely an offer for sale, the proceeds will be received by the selling shareholders and promoters.

So, should you subscribe to the CORONA Remedies IPO?

IPOs may dominate headlines, but they aren’t the path to long-term wealth. For most investors, jumping into every new listing does little more than add noise to the portfolio — especially when many IPOs struggle to deliver meaningful listing gains.

This is where Value Research Stock Advisor comes in. We help you identify companies with durable business models, consistent performance and the ability to compound wealth through multiple market cycles, well beyond the excitement of their IPO debut.

Explore Stock Advisor today

Also read: The great Indian IPO lottery